Skip to main
GOSS
GOSS logo

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 40%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc is positioned favorably due to its promising clinical pipeline, particularly with seralutinib, which has shown significant efficacy in reducing NT-proBNP and improving heart function in patients with pulmonary arterial hypertension (PAH). The anticipated initiation of a Phase 3 trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the second half of 2025 highlights the potential for expanding its market footprint amid substantial unmet medical needs. With key data readouts and multiple catalysts expected in the near term, Gossamer Bio's strategic direction underscores a positive outlook for the company.

Bears say

Gossamer Bio Inc. faces significant challenges due to the competitive landscape in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), particularly as studies indicate poor prognosis among afflicted patients. The potential inability to gain necessary product labels and effectively market its pipeline treatments could hinder the company's market traction and financial performance. Additionally, the possibility of shareholder dilution, compounded by an already limited therapeutic landscape, raises concerns about the company's ability to meet or exceed market expectations, further contributing to a negative financial outlook.

GOSS has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 40% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 15 analysts, GOSS has a Buy consensus rating as of Sep 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.